Vistagen to Present at Psych Congress 2026

Vistagen (VTGN) will present Phase 3 fasedienol nasal spray data showing a positive efficacy signal in public speaking challenge participants with very severe social anxiety disorder at Psych Congress in New Orleans on September 17–18, 2026.

Rhea-AI Summary

Vistagen (VTGN) will present Phase 3 fasedienol nasal spray data showing a positive efficacy signal in public speaking challenge participants with very severe social anxiety disorder at Psych Congress in New Orleans on September 17–18, 2026.

The poster, number 230, is titled “Fasedienol Nasal Spray for Acute Treatment of Social Anxiety Disorder in Participants With Baseline LSAS Scores ≥95: Subgroup Analyses from Two Multi-center, Randomized, Placebo-controlled Public Speaking Challenge Trials.”

Key Figures

LSAS threshold: ≥95

LSAS threshold

≥95

Very severe social anxiety disorder subgroup

Key Terms

intranasal, placebo-controlled

2 terms

intranasal medical

"a new class of intranasal product candidates called pherines"

Administration or delivery of a drug or vaccine through the nose, typically via a spray or drops that are absorbed by the nasal tissues. For investors, intranasal products can matter because they often offer easier, needle-free use, faster onset of effect, and potential cost or compliance advantages that can widen a product’s market and affect regulatory review, manufacturing complexity, and commercial prospects — similar to how a convenient app can outsell a clunky desktop program.

placebo-controlled medical

"Multi-center, randomized, placebo-controlled public speaking challenge trials"

"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Poster presentation highlights positive efficacy signal for fasedienol nasal spray in study participants with very severe social anxiety disorder

SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company leveraging nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced it will present data highlighting a positive efficacy signal for its Phase 3 product candidate, fasedienol nasal spray, in public speaking challenge study participants with very severe social anxiety disorder at Psych Congress in New Orleans on Thursday, September 17, and Friday, September 18, 2026.

Poster Presentation
Date: Thursday, September 17, 2026, and Friday, September 18, 2026
Title: Fasedienol Nasal Spray for Acute Treatment of Social Anxiety Disorder in Participants With Baseline LSAS Scores ≥95: Subgroup Analyses from Two Multi-center, Randomized, Placebo-controlled Public Speaking Challenge Trials
Authors: Azmi Nasser, PhD, Michael R. Liebowitz, MD, Aubrey Reid, MS, Imogene Dunn, PhD, Eric Davis, MD, Ross A. Baker, PhD, Angel Angelov, MD, Louis Monti, MD, PhD
Poster Number: 230

About Vistagen
Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of rapid-onset neurocircuitry-focused intranasal product candidates called pherines. Vistagen’s pherine product candidates are designed to achieve therapeutic benefits without requiring absorption into the blood or uptake into the brain, giving them the potential to be a safer alternative to other pharmacological options, if successfully developed and approved. Vistagen’s most advanced intranasal pherine product candidates are fasedienol for the acute treatment of social anxiety disorder, itruvone for treatment of major depressive disorder, and refisolone for treatment of vasomotor symptoms (hot flashes) due to menopause. Connect at www.Vistagen.com

Investor Inquiries:
IR@vistagen.com

Media Inquiries:
media@vistagen.com

FAQ

What specific data will Vistagen present about fasedienol nasal spray at Psych Congress 2026?

The company will present subgroup analyses of fasedienol nasal spray for the acute treatment of social anxiety disorder in participants with baseline Liebowitz Social Anxiety Scale (LSAS) scores ≥95, based on two multi-center, randomized, placebo-controlled public speaking challenge trials.

When and where is Vistagen’s poster on fasedienol scheduled at Psych Congress?

The poster presentation is scheduled for Thursday, September 17, 2026, and Friday, September 18, 2026, at Psych Congress in New Orleans, and is listed as poster number 230.